Physician profile

Todd Hrabak

Allergy · Glendale, AZ

NPI 1801821152

$401,131.94

in general payments reported to CMS, 2019-2025

41 companies · $179K in 2025

The $179K reported for 2025 was more than what 99% of Allergy providers received nationally (typical 2025 total: $1,129).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program$231,934.44
Travel and Lodging$49,762.97
Food and Beverage$15,252.84
Consulting Fee$286.94
Education$168.19

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Csl Behring $156,295.01 2019-2025 Hizentra, Haegarda
Takeda Pharmaceuticals U.S.A., INC. $144,122.04 2020-2025 Cuvitru, Hyqvia, Glassia
Ars Pharmaceuticals Operations, INC. $62,695.23 2025 Neffy
Bio Products Laboratory USA, INC. $12,332.18 2022-2023 Gammaplex, Coagadex
Shire North American Group INC $8,607.36 2019
Gc Biopharma USA, INC. $2,908.62 2024-2025 Alyglo, Alyglo
Novartis Pharmaceuticals Corporation $2,875.45 2019-2025
Genentech USA, INC. $1,755.61 2019-2025 Xolair
Glaxosmithkline, LLC. $1,725.02 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Astrazeneca Pharmaceuticals Lp $1,361.85 2019-2025 Fasenra, Airsupra, Breztri
Genzyme Corporation $1,272.42 2019-2025
Grifols USA, LLC $934.33 2019-2025 Xembify, Prolastin-C Liquid
Boehringer Ingelheim Pharmaceuticals, INC. $572.00 2019-2024 Spiriva Respimat, Stiolto Respimat, Ofev
Regeneron Healthcare Solutions, INC. $490.87 2019-2025 Dupixent
Actelion Pharmaceuticals US, INC. $487.45 2019-2024 Uptravi, Opsumit
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Pfizer INC. $427.34 2020-2025
Electromed, INC. $330.76 2021-2025 Smartvest
Adma Biomanufacturing LLC $309.90 2020-2025
Pharming Healthcare, INC. $237.22 2021-2025 Ruconest
Optinose US, INC. $144.64 2020-2022
Teva Pharmaceuticals USA, INC. $132.65 2019-2022
Amgen INC. $107.82 2019-2025
Octapharma USA, INC. $102.12 2021-2024 Octagam Immune Globulin (Human)
Baxter Healthcare $99.11 2022-2025 Hillrom - Vest System Model 105 Home Care
Abbott Laboratories $97.25 2019-2024 Proclaim, Prodigy
Abbvie INC. $91.42 2021-2023
Boston Scientific Corporation $79.29 2019-2024
Philips North America LLC $73.13 2019-2024 (8874) Incourage
Kedrion Biopharma, INC. $58.24 2023-2024 Koate, Gammaked, Kedrab
Kaleo, INC. $56.09 2022
Advanced Respiratory, INC $55.87 2020-2021
Blueprint Medicines Corporation $51.47 2023-2024 Ayvakit
United Therapeutics Corporation $49.17 2021-2024
Phadia US INC. $36.98 2022-2024 Immunocap
Merck Sharp & Dohme LLC $35.72 2024-2025 Capvaxive, Vaxneuvance, Gardasil
Biocryst US Sales Co., LLC $32.10 2024 Orladeyo
Springworks Therapeutics, INC. $22.12 2025 Gomekli
Inogen, INC. $20.10 2024
Mylan Specialty L.P. $19.77 2022
Insmed, INC. $13.32 2024 Arikayce
Aimmune Therapeutics, INC. $12.90 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Todd Hrabak

$401,131.94

in general payments reported 2019-2025

Years
2019-2025
Top company
Csl Behring
Context
The $179K reported for 2025 was more than what 99% of Allergy providers received nationally (typical 2025 total: $1,129).

https://glasscript.com/doctor/353812/todd-hrabak

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.